Q2 2026 Sera Prognostics Inc Earnings Call Transcript
Key Points
- Sera Prognostics Inc (SERA) achieved a major policy milestone with Illinois Medicaid coverage legislation, providing access to its preterm birth test for tens of thousands of pregnancies annually.
- The company exceeded its goal for payer engagement, now in discussions with more than 20 payers across over 20 states, driven by referrals and growing market awareness.
- A new subgroup analysis of the PRIME trial published in July showed a 22% reduction in NICU admissions and a 30% reduction in severe neonatal morbidity in first-time mothers.
- Sera Prognostics Inc (SERA) launched its fourth partnership program with a national payer, expanding the implementation of its test-guided care and remaining on track to establish five to seven commercial programs.
- The company's cash position of $80.3 million is expected to fund operations through significant adoption and commercial milestones into 2029.
- Sera Prognostics Inc (SERA) is advancing its European strategy, with a CE marking submission for its LISA-based assay platform expected in the fourth quarter of 2026.
- Revenue remains minimal at $30,000 for the quarter, reflecting the early stage of commercialization and the lengthy process of converting market access into testing volume.
- The timeline for meaningful revenue contribution from the Illinois Medicaid legislation is expected to be slow, with penetration rates of only 1-2% projected for the first full year.
- The company's net loss widened to $9.1 million in Q2 2026, up from $8.0 million in the same period last year.
- The CE marking submission for Europe has been delayed to the fourth quarter of 2026 due to the need for additional performance testing, pushing back potential European market entry.
- The process of converting payer discussions into active contracts and reimbursement is lengthy, with policy reviews taking 9-12 months and implementation periods of 6-9 months before utilization scales.
- Sera Prognostics Inc (SERA) faces a significant execution challenge in Illinois, requiring contracting with five separate managed Medicaid organizations and extensive provider onboarding before volumes can ramp.
Good afternoon, ladies and gentlemen, and welcome to Sara Prognostics Second Quarter 2026 Financial Results Conference Call.
At this time, all lines are in this and only mode.
Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press *0 for the operator. This call is being recorded on Wednesday, August 12, 2026.
I would now like to turn the conference over to Jennifer Zibuda, Head of Investor Relations. Please go ahead.
Thank you, operator. Welcome to Sara Prognostics' second-quarter 2026 earnings conference call.
Earlier today, Sara reported financial results for the quarter ended June 30, 2026. Joining me on today's call are Jenia Lyngard, President and Chief Executive Officer, and Austin Eritz, Chief Financial Officer.
Following our prepared remarks, we will open the call for questions.
A copy of today's earnings release can be found in the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
